Lepszy H, Irmscher K, Wiegelmann W, Solbach H G, Krüskemper H L
Dtsch Med Wochenschr. 1976 May 28;101(22):857-61. doi: 10.1055/s-0028-1104184.
Urinary excretion of hydroxyproline was examined with the Hypronosticon test in 25 patients with acromegaly (13 men, 12 women) and 15 healthy persons. At the same time, plasma levels and urinary excretion of phosphorus and calcium were also measured. Patients with active acromegaly had a significantly higher urinary hydroxyproline output (32.55 +/- 8.68 mg/24 h m2) than healthy persons (12.12 +/- 2.33 mg/24 h-m2). They also excreted considerably more hydroxyproline than patients with successfully treated acromegaly. Effective treatment was proved by STH levels and good suppressibility by 100 mg glucose. Unsucessfully treated patients, on the contrary, had a raised urinary excretion of hydroxyproline (31.23 +/- 16.61 mg/24 h-m2) and high fasting plasma levels of somatotropic hormone. Hydroxyprolinuria proved, therefore, of value in assessing the development and treatment of acromegaly.
采用羟脯氨酸检测法对25例肢端肥大症患者（13例男性，12例女性）和15名健康人进行了尿羟脯氨酸排泄情况检查。同时，还测定了血浆磷、钙水平及尿磷、钙排泄量。活动期肢端肥大症患者的尿羟脯氨酸排出量（32.55±8.68mg/24h·m²）显著高于健康人（12.12±2.33mg/24h·m²）。他们排出的羟脯氨酸也比肢端肥大症治疗成功的患者多得多。生长激素水平及100mg葡萄糖的良好抑制性证明治疗有效。相反，治疗未成功的患者尿羟脯氨酸排泄量升高（31.23±16.61mg/24h·m²），且空腹血浆生长激素水平较高。因此，羟脯氨酸尿症在评估肢端肥大症的病情发展及治疗方面具有价值。
